S

Syndax Pharmaceuticals

D

SNDX

USD

0.16

(0.7491%)

Market Closed

38,560.00

Volume

-3.94

EPS

-

Div Yield

-6.329412

P/E

1,831,273,624.16

Market Cap

Today

1.7975%

1 Week

14.104%

1 Month

17.724%

6 Months

-7.081%

12 Months

47.296%

Year To Date

-0.370%

All Time

0%

Related Instruments

Title:
Syndax Pharmaceuticals

Sector:

Healthcare

Industry:

Biotechnology

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Do you need help or have a question?